Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer

  1. Paz-Ares, L.G.
  2. Pérol, M.
  3. Ciuleanu, T.-E.
  4. Kowalyszyn, R.D.
  5. Reck, M.
  6. Lewanski, C.R.
  7. Syrigos, K.
  8. Arrieta, O.
  9. Prabhash, K.
  10. Park, K.
  11. Pikiel, J.
  12. Göksel, T.
  13. Lee, P.
  14. Zimmermann, A.
  15. Carter, G.C.
  16. Alexandris, E.
  17. Garon, E.B.
Aldizkaria:
Lung Cancer

ISSN: 1872-8332 0169-5002

Argitalpen urtea: 2017

Alea: 112

Orrialdeak: 126-133

Mota: Artikulua

DOI: 10.1016/J.LUNGCAN.2017.05.021 GOOGLE SCHOLAR